Merck and Bayer Report Results of Vericiguat in P-III VICTORIA Study for Patients with Worsening Chronic Heart Failure

Merck’s Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)


  • The P-III VICTORIA study involves assessing of Vericiguat vs PBO in combination with available HF therapies in 5,050 patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) following a decompensation event across 600 centers in 42 countries
  • The P-III VICTORIA study resulted in meeting its 1EPs i.e, reduction in heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with HFrEF
  • Vericiguat is an investigational soluble guanylate cyclase (sGC) stimulator, jointly developed by Merck and Bayer. In Oct’2014, Bayer and Merck entered into a WW collaboration to develop sGC modulators

Click here to­ read full press release/ article | Ref: Merck | Image: Brands Vietnam